Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as prophylaxis and pre-emptive therapy, and management of cytomegalovirus disease. Antiviral drugs including maribavir and letermovir are in development and prospective clinical trials have recently been completed. However, management of patients with resistant or refractory cytomegalovirus infection or cytomegalovirus disease is a challenge. In this Review we summarise the reviewed literature and the recommendations of the ECIL 7 for management of cytomegalovirus in patients with haematological malignancies.
- MeSH
- antivirové látky terapeutické užití MeSH
- benzimidazoly terapeutické užití MeSH
- cytomegalovirové infekce diagnóza etiologie prevence a kontrola MeSH
- Cytomegalovirus imunologie MeSH
- ganciklovir terapeutické užití MeSH
- hematologické nádory farmakoterapie MeSH
- leukemie komplikace farmakoterapie MeSH
- lidé MeSH
- ribonukleosidy terapeutické užití MeSH
- směrnice pro lékařskou praxi jako téma * MeSH
- transplantace hematopoetických kmenových buněk škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
